SCHEMBL17390237

SCHEMBL17390237

CCCc1nn(C)c2c(=O)[nH]c(-c3cc(NC4CCN(c5ncc(C(=O)NO)cn5)CC4)ccc3OCC)nc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 20/20 1.00
HDAC1 Q13547 20/20 1.00
HDAC6 Q9UBN7 20/20 1.00
HDAC2 Q92769 15/20 1.00
HDAC3 O15379 6/20 1.00
NCOR2 Q9Y618 6/20 1.00
PDE9A O76083 1/20 0.70
PDE6C P51160 1/20 0.70
PDE3A Q14432 1/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17390230 0.93 PDE5A (0.88) PDE5AHDAC1HDAC6HDAC2HDAC3
SCHEMBL17390207 0.92 PDE5A (0.85) PDE5AHDAC1HDAC6HDAC2HDAC3
SCHEMBL16003677 0.91 PDE5A (1.00) PDE5AHDAC1HDAC6HDAC2HDAC3
SCHEMBL17411198 0.91 PDE5A (1.00) PDE5AHDAC1HDAC6HDAC2HDAC3
SCHEMBL17404879 0.89 PDE5A (1.00) PDE5AHDAC1HDAC6HDAC2HDAC3
SCHEMBL16003920 0.88 PDE5A (0.90) PDE5AHDAC1HDAC6HDAC2HDAC3
SCHEMBL17390118 0.88 PDE5A (0.90) PDE5AHDAC1HDAC6HDAC2HDAC3
SCHEMBL17390116 0.88 PDE5A (0.78) PDE5AHDAC1HDAC6HDAC2HDAC3
SCHEMBL16003918 0.88 PDE5A (0.80) PDE5AHDAC1HDAC6HDAC2HDAC3
SCHEMBL16003779 0.87 PDE5A (0.78) PDE5AHDAC1HDAC6HDAC2HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2961741-B1 NOVEL COMPOUNDS AS DUAL INHIBITORS OF PHOSPHODIESTERASES AND HISTONE DEACETYLASES FUND PARA LA INVESTIG MEDICA APLICADA (ES) 2017-04-05 EP disclosed
EP-2961741-B1 NOVEL COMPOUNDS AS DUAL INHIBITORS OF PHOSPHODIESTERASES AND HISTONE DEACETYLASES FUND PARA LA INVESTIG MEDICA APLICADA (ES) 2017-04-05 EP disclosed
US-9573956-B2 Compounds as dual inhibitors of phosphodiesterases and histone deacetylases FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA (ES) 2017-02-21 US disclosed
US-9573956-B2 Compounds as dual inhibitors of phosphodiesterases and histone deacetylases FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA (ES) 2017-02-21 US disclosed
US-20160002246-A1 NOVEL COMPOUNDS AS DUAL INHIBITORS OF PHOSPHODIESTERASES AND HISTONE DEACETYLASES FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA (ES) 2016-01-07 US disclosed
US-20160002246-A1 NOVEL COMPOUNDS AS DUAL INHIBITORS OF PHOSPHODIESTERASES AND HISTONE DEACETYLASES FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA (ES) 2016-01-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160002246-A1 NOVEL COMPOUNDS AS DUAL INHIBITORS OF PHOSPHODIESTERASES AND HISTONE DEACETYLASES PDE1A, HDAC1, HDAC2 PDE5A 24/4885HDAC1 2/4885HDAC6 12/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.